

WHO International Standard 1st International Standard for Vascular Endothelial Growth Factor 165 (VEGF165) NIBSC code: 19/246 Instructions for use (Version 1.0, Dated 18/05/2023)

§

1. INTENDED USE

The preparation coded 19/246 was established as the 1st WHO International Standard for human vascular endothelial growth factor 165 (VEGF165) by the WHO Expert Committee on Biological Standardization in 2023, following evaluation in an International Collaborative Study. This preparation is intended to calibrate assays used for evaluating in-vitro biological activities of VEGF165.

2. CAUTION

This preparation is not for administration to humans or animals

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

The preparation has been assigned a potency of 9,000 International Units (IU) of activity per ampoule relative to WHO Reference Reagent (02/286) on the basis of the International Collaborative Study. Therefore, the unitage is in continuity with the previous Reference Reagent.

4. CONTENTS

Country of origin of biological material: United Kingdom.

Each ampoule contains the residue after freeze-drying of 1.0 ml of a solution containing:

Approximate 10 µg VEGF165 10 mM citric acid pH 5.2 2 mg/ml trehalose 0.5% human serum albumin

The VEGF165 protein was expressed in in Spodoptera frugiperda 21 (Sf21) cells.

5. STORAGE

Unopened ampoules should be stored at -20°C.

Following reconstitution, freezing of ampoule contents is not recommended. However, the standard can be used for a limited duration post-reconstitution e.g., up to 7 days at 4°C post-storage.

Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory



6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freezedried material prior to reconstitution

Reconstitution: dissolve the total contents in 1 ml of sterile distilled water. This solution contains VEGF165 at a concentration of 9,000 International Units per ml. For further dilutions, use a suitable buffer containing carrier protein to minimise loss by surface adsorption.

8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

It is the policy of WHO not to assign an expiry date to their international reference materials. Accelerated degradation studies have indicated that this material is suitably stable, when stored at -20°C or below, for the assigned values to remain valid until the material is withdrawn or replaced. These studies have also shown that the material is suitably stable for shipment at ambient temperature without any effect on the assigned values.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES

This standard was produced under WHO guidelines cited in the WHO Technical Reports Series, No. 932, 2006, Annex 2.

Report on the Collaborative Study for proposed 1st International Standard for human vascular endothelial growth factor 165 (VEGF165) WHO/BS/2023.2443

https://www.who.int/publications/m/item/who-bs-2023.2443

10. ACKNOWLEDGEMENTS

We are very grateful to Bio-Techne for supplying the VEGF165 protein for use as candidate standard and to the participating laboratories for their great support and important contributions to the collaborative study.

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctIm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx





12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties			
Physical appearance:		Corrosive:	No
Freeze-dried powder			
Stable: Yes		Oxidising:	No
Hygroscopi Yes		Irritant:	No
c:			
Flammable: No		Handling: Se	e caution, Section 2
Other Contains material of human origin			
(specify):			
Toxicological properties			
Effects of inhalation: Not		established, avoid inhalation	
Effects of ingestion: Not		established, avoid ingestion	
Effects of skin	Not	established,	avoid contact with
absorption:	skin		
Suggested First Aid			
Inhalation: Seek	Seek medical advice		
Ingestion: Seek	Seek medical advice		
Contact with Wash	Wash with copious amounts of water. Seek		
eyes: medical advice			
Contact with Wash thoroughly with water.			
skin:			
Action on Spillage and Method of Disposal			

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.



16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying. Net weight: 5 mg Toxicity Statement: Toxicity not assessed

Veterinary certificate or other statement if applicable. Attached: No

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards

http://www.who.int/bloodproducts/publications/TRS932Annex2_l nter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.

